Lupin Limited has informed the Exchange about Transcript of Q1 FY2026 Earnings Conference Call.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin reported strong Q1 FY26 results with sales of INR 6,164 crore, up 11.8% YoY. EBITDA grew 27.6% YoY to INR 1,641 crore with margin expansion of 330 bps to 26.6%. US business grew 22.3% YoY to USD 282 million, boosted by Tolvaptan launch with sole FTF exclusivity. India Formulations grew 8.6% YoY while Other Developed Markets grew 17% (Europe up 28%). Management reaffirmed full-year FY26 EBITDA margin guidance of 24-25% and expects R&D spend of ~8.5% of sales. Key launches in pipeline include Liraglutide (October), Risperdal Consta (September 2025 goal date), Pegfilgrastim, Ranibizumab (FY27), and NaMuscla (FY29). Net cash position improved significantly to INR 1,239 crore from INR 310 crore.
Strong quarterly performance with margin expansion and robust product pipeline supports positive outlook. Management guided for high single-digit growth in FY27, indicating confidence despite expected competition on key products like Mirabegron. Stock likely to react positively given beat on margins and clear growth catalysts.